Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.02)
# 1,429
Out of 4,723 analysts
138
Total ratings
40.43%
Success rate
0.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $33.34 | +49.97% | 9 | Jan 10, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 → $7.5 | $4.03 | +86.10% | 5 | Dec 13, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $39 | $18.58 | +109.90% | 18 | Dec 4, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $200 | $120.23 | +66.35% | 16 | Nov 22, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $8.53 | +134.47% | 8 | Nov 20, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $27 → $25 | $10.69 | +133.86% | 14 | Nov 13, 2024 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6 → $6.6 | $3.36 | +96.43% | 10 | Nov 11, 2024 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $54.16 | +73.56% | 11 | Nov 11, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Neutral | n/a | $0.70 | - | 11 | Nov 6, 2024 | |
| CARA Cara Therapeutics | Downgrades: Neutral | n/a | $4.75 | - | 13 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $61 | $55.24 | +10.43% | 8 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $6.17 | +21.56% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $1.23 | +550.41% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $5.23 | +1,037.67% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $3.92 | +4,951.02% | 2 | May 7, 2021 |
Collegium Pharmaceutical
Jan 10, 2025
Reiterates: Buy
Price Target: $50
Current: $33.34
Upside: +49.97%
Trevi Therapeutics
Dec 13, 2024
Reiterates: Buy
Price Target: $6 → $7.5
Current: $4.03
Upside: +86.10%
Pacira BioSciences
Dec 4, 2024
Reiterates: Buy
Price Target: $39
Current: $18.58
Upside: +109.90%
Jazz Pharmaceuticals
Nov 22, 2024
Reiterates: Buy
Price Target: $200
Current: $120.23
Upside: +66.35%
Zevra Therapeutics
Nov 20, 2024
Reiterates: Buy
Price Target: $20
Current: $8.53
Upside: +134.47%
Avadel Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $27 → $25
Current: $10.69
Upside: +133.86%
Xeris Biopharma Holdings
Nov 11, 2024
Maintains: Buy
Price Target: $6 → $6.6
Current: $3.36
Upside: +96.43%
ANI Pharmaceuticals
Nov 11, 2024
Reiterates: Buy
Price Target: $94
Current: $54.16
Upside: +73.56%
Verrica Pharmaceuticals
Nov 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.70
Upside: -
Cara Therapeutics
Jun 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.75
Upside: -
May 13, 2024
Maintains: Buy
Price Target: $57 → $61
Current: $55.24
Upside: +10.43%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $6.17
Upside: +21.56%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.23
Upside: +550.41%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $5.23
Upside: +1,037.67%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $3.92
Upside: +4,951.02%